Physician profile
Robert Muldoon
NPI 1841277589
$16,748.14
in general payments reported to CMS, 2019-2025
76 companies · $2,553 in 2025
The $2,553 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,301 · 2020: $1,971 · 2021: $2,201 · 2022: $2,614 · 2023: $2,491 · 2024: $2,616 · 2025: $2,553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,621 · Education: $39.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,620.84 |
| Education | $39.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,529.89 | 2019-2025 | Imfinzi, Enhertu, Lynparza |
| Novartis Pharmaceuticals Corporation | $1,444.21 | 2019-2025 | |
| Pfizer INC. | $1,262.19 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $745.81 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Celgene Corporation | $617.90 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Lilly USA, LLC | $600.25 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Glaxosmithkline, LLC. | $585.36 | 2020-2025 | Jemperli, Zejula, Ojjaara |
| Exelixis INC. | $573.09 | 2019-2025 | Cabometyx |
| Eisai INC. | $560.96 | 2020-2025 | |
| Janssen Biotech, INC. | $524.57 | 2019-2025 | Darzalex, Tecvayli, Erleada |
| E.R. Squibb & Sons, L.L.C. | $511.18 | 2019-2025 | Opdivo, Reblozyl |
| Incyte Corporation | $447.24 | 2019-2025 | Jakafi, Monjuvi |
| Kite Pharma, INC. | $367.81 | 2019-2023 | Yescarta |
| Gilead Sciences, INC. | $344.92 | 2019-2025 | Trodelvy |
| Seagen INC. | $339.12 | 2019-2023 | Adcetris, Padcev, Tukysa |
Show all 76 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Muldoon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.